Research programme: cancer therapeutics - Redx Pharma

Drug Profile

Research programme: cancer therapeutics - Redx Pharma

Alternative Names: Bruton's tyrosine kinase inhibitor - Redx Pharma; Indoleamine-2,3-dioxygenase inhibitor - Redx Pharma; porcupine inhibitor - Redx Pharma; RXC-004; Smoothened inhibitor - Redx Pharma; T-cell target agonists - Redx Pharma

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator Redx Pharma
  • Developer Horizon Discovery; Redx Pharma
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; PORCN protein inhibitors; Raf kinase inhibitors; SMO protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Basal cell cancer
  • Research Colorectal cancer
  • No development reported Cancer

Most Recent Events

  • 29 Nov 2016 Preclinical data presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in United Kingdom
  • 16 Sep 2015 Preclinical trials in Basal cell cancer in United Kingdom (Topical) (Redx Pharma pipeline, September 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top